Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7087)
All Articles published online
|
Publishing Process of This Article
|
Apr 10, 2016 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol 2016; 7(2): 253-257 [PMID: 27081648 DOI: 10.5306/wjco.v7.i2.253] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v7/i2/253.htm |
| Number | Citing Articles |
| 1 |
Alok Singh, Ajaya K. Sahoo, Debadulal Biswal, Pranav G. Sheth, Suryaprakash Dhaneria, Dhyuti Gupta. The Profile of Use of Rituximab in Tertiary Care Hospitals of Central India. Journal of Pharmacy and Bioallied Sciences 2022; 14(4): 191 doi: 10.4103/jpbs.jpbs_520_22
|
| 2 |
Matthijs Luxen, Matijs van Meurs, Grietje Molema. Unlocking the Untapped Potential of Endothelial Kinase and Phosphatase Involvement in Sepsis for Drug Treatment Design. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.867625
|
| 3 |
Silvia Paddock, Hamed Abedtash, Jacqueline Zummo, Samuel Thomas. Proof-of-concept study: Homomorphically encrypted data can support real-time learning in personalized cancer medicine. BMC Medical Informatics and Decision Making 2019; 19(1) doi: 10.1186/s12911-019-0983-9
|
| 4 |
Vivek Dwivedi, Shahnawaz Sameem, Mahfoozur Rahman, Prateek Pathak, Amita Verma. Hormone Related Cancer Mechanistic and Nanomedicines. 2022; : 111 doi: 10.1007/978-981-19-5558-7_6
|
| 5 |
Kathrin Halfter, Barbara Mayer. Bringing 3D tumor models to the clinic – predictive value for personalized medicine. Biotechnology Journal 2017; 12(2) doi: 10.1002/biot.201600295
|
| 6 |
Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Ricard Mesía, Ana Clopés. Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience. Pharmacology Research & Perspectives 2024; 12(1) doi: 10.1002/prp2.1167
|
| 7 |
Xiaoyi Chen, Shunlong Ou, Jing Luo, Zhisan He, Qian Jiang. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1374549
|
| 8 |
Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Javier Martínez, Ricard Mesía, Ana Clopés. Real‐world treatment outcomes of medicines used in special situations (off‐label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution. Cancer Medicine 2023; 12(16): 17112 doi: 10.1002/cam4.6360
|
| 9 |
Bishal Gyawali, Aaron S. Kesselheim. The promise of ESCAT: a new system for evaluating cancer drug–target pairs. Nature Reviews Clinical Oncology 2019; 16(3): 147 doi: 10.1038/s41571-018-0110-3
|
| 10 |
Nadine Umbach, Tim Beißbarth, Annalen Bleckmann, Gunnar Duttge, Laura Flatau, Alexander König, Jessica Kuhn, Julia Perera-Bel, Julia Roschauer, Thomas G. Schulze, Mark Schweda, Alexander Urban, Anja Zimmermann, Ulrich Sax. Clinical application of genomic high-throughput data: Infrastructural, ethical, legal and psychosocial aspects. European Neuropsychopharmacology 2020; 31: 1 doi: 10.1016/j.euroneuro.2019.09.008
|
| 11 |
E. V. Karabina, D. D. Sakaeva, O. N. Lipatov. Off-Label Drug Use in Oncology. Creative surgery and oncology 2022; 12(2): 164 doi: 10.24060/2076-3093-2022-12-2-164-171
|
| 12 |
Ariadna Tibau, Thomas J. Hwang, Consolacion Molto, Jerry Avorn, Aaron S. Kesselheim. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology 2024; 10(5): 634 doi: 10.1001/jamaoncol.2024.0194
|
| 13 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 695 doi: 10.1016/B978-0-12-809400-6.00029-9
|
| 14 |
Jan R.R. Lewis, Ian Kerridge, Wendy Lipworth. Use of Real-World Data for the Research, Development, and Evaluation of Oncology Precision Medicines. JCO Precision Oncology 2017; (1): 1 doi: 10.1200/PO.17.00157
|
| 15 |
Jean‐David Zeitoun, Gabriel Baron, Alexandre Vivot, Ignacio Atal, Nicholas S Downing, Joseph S Ross, Philippe Ravaud. Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional study. International Journal of Cancer 2018; 142(2): 414 doi: 10.1002/ijc.31061
|
| 16 |
|
| 17 |
Grace Lovia Allotey-Babington, Henry Nettey, Martin J. D'Souza. Docetaxel-dasatinib combination: A strategy to overcome unfavorable treatment outcomes due to dose reduction. Journal of Drug Delivery Science and Technology 2021; 61: 102085 doi: 10.1016/j.jddst.2020.102085
|
| 18 |
A. Prawira, T.J. Pugh, T.L. Stockley, L.L. Siu. Data resources for the identification and interpretation of actionable mutations by clinicians. Annals of Oncology 2017; 28(5): 946 doi: 10.1093/annonc/mdx023
|
| 19 |
Vivek A. Upadhyay, Bruce E. Johnson, Adam B. Landman, Michael J. Hassett. Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort. JCO Precision Oncology 2022; (6) doi: 10.1200/PO.21.00232
|
| 20 |
Lelia Maria de Almeida Carvalho, Sandra de Oliveira Sapori Avelar, Alyson Haslam, Jennifer Gill, Vinay Prasad. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Network Open 2019; 2(11): e1916091 doi: 10.1001/jamanetworkopen.2019.16091
|
| 21 |
Mir Lim, David S. Shulman, Holly Roberts, Anran Li, Jessica Clymer, Kira Bona, Hasan Al‐Sayegh, Clement Ma, Steven G. DuBois. Off‐label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Medicine 2020; 9(18): 6658 doi: 10.1002/cam4.3349
|
| 22 |
Victor Desmond Mandel, Matelda Medri, Ausilia Maria Manganoni, Laura Pavoni, Francesco De Rosa, Simone Ribero, Flavia Foca, Daniele Andreis, Laura Mazzoni, Serena Magi, Francesca Farnetani, Marco Palla, Paola Ulivi, Ignazio Stanganelli. Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications. Journal of Dermatological Treatment 2022; 33(3): 1368 doi: 10.1080/09546634.2020.1817838
|
| 23 |
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang. Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States. Melanoma Research 2024; 34(5): 457 doi: 10.1097/CMR.0000000000000990
|
| 24 |
Lior Zimmerman, Ori Zelichov, Arie Aizenmann, Zohar Barbash, Michael Vidne, Gabi Tarcic. A Novel System for Functional Determination of Variants of Uncertain Significance using Deep Convolutional Neural Networks. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-61173-1
|
| 25 |
Shoyo Shibata, Maiko Matsushita, Katsura Tsukamoto, Koji Chiba, Koken Ozaki, Takeshi Suzuki. A Study on the Description of Anticancer Drug Combination Therapy in the Package Insert in Japan. BPB Reports 2020; 3(5): 157 doi: 10.1248/bpbreports.3.5_157
|
| 26 |
Doah Cho, Sarah J. Lord, John Simes, Wendy Cooper, Michael Friedlander, Susie Bae, Chee Khoon Lee. Next-generation sequencing, should I use anti-HER2 therapy for HER2-amplified tumors off-label? Illustrating an extrapolation framework. Therapeutic Advances in Medical Oncology 2022; 14 doi: 10.1177/17588359221112822
|
| 27 |
D. Levêque. Pharmacie Clinique Pratique en Oncologie. 2020; : 78 doi: 10.1016/B978-2-294-76375-5.00009-9
|
| 28 |
Kailu Wang, Ho-Man Shum, Carrie Ho-Kwan Yam, Yushan Wu, Eliza Lai-Yi Wong, Eng-Kiong Yeoh. Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling. Applied Health Economics and Health Policy 2024; 22(6): 849 doi: 10.1007/s40258-024-00912-1
|